Usana Health Sciences Inc 's ability to collect accounts receivable sequentially worsen to 280.96, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Average collection period, for Usana Health Sciences Inc 's accounts receivable remained unchanged at 1 days, in the Jul 04 2026 quarter.

If we take a look into Consumer Non Cyclical sector 47 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jul 04 2026 from 348 to 601.

What is Receivable Turnover Ratio?
What is Usana Health Sciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

USNA Receivables Turnover Ratio	(Jul 04 2026) II. Quarter	(Apr 04 2026) I. Quarter	(Jan 03 2026) IV. Quarter	(Sep 27 2025) III. Quarter	(Jun 28 2025) II. Quarter
Y / Y Receivable Change	-	-	-	-	-
Y / Y Revenue Change	-5.26 %	0.28 %	5.95 %	6.45 %	10.88 %
Receivable Turnover Ratio (TTM)	280.96	383.18	-	-	-
USNA's Total Ranking	# 601	# 348	# 570	# 510	# 337
Accounts Receivable average collection period days	1	1	-	-	-
Seq. Receivable Change	-65.44 %	-	-	-	-
Seq. Revenue Change	-10.61 %	10.14 %	6.55 %	-9.68 %	-5.39 %

Receivable Turnover Company Ranking
Within:	No.
Legal Cannabis Industry	# 5
Consumer Non Cyclical Sector	# 48
Overall Market	# 601

Receivable Turnover Ratio Statistics
High	Average	Low
2.5	1.97	1.23
(Jun 29 2013)		(Sep 27 2025)

USNA Company Profile • Back to USNA Efficiency Comparisons • Compare USNA Receivables Turnover Ratio to its Competitors

Financial Statements
Usana Health Sciences Inc 's Accounts Receivable	$ 3 Millions	Visit USNA's Balance sheet
Usana Health Sciences Inc 's Sales TTM	$ 913 Millions	Visit USNA's Income Statement
Sources of USNA's Revenues		Visit USNA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Legal Cannabis Industry Accounts Receivable Turnover Trends and Statistics
Consumer Non Cyclical Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
USNA's Receivable Turnover Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
USNA's Growth Rates	USNA's Roa	USNA's Inventory Turnover Ratio	USNA's Dividend Comparisons
USNA's Profitability Ratios	USNA's Roi	USNA's Asset Turnover Ratio	USNA's Dividend Growth
USNA's Valuation Ratios	USNA's Roe	USNA's Financial Strength Ratios	USNA's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jul 04 2026, within Consumer Non Cyclical Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jul 04 2026	Receivable at quarter ending Jul 04 2026
Nocera Inc	311.96	$ 10.023 Millions	$ 0.032 Millions
Usana Health Sciences Inc	280.96	$ 912.702 Millions	$ 3.249 Millions
Beeline Holdings Inc	256.16	$ 9.542 Millions	$ 0.037 Millions
Coca cola Consolidated Inc	152.86	$ 7,691.262 Millions	$ 50.317 Millions
Mannatech Inc	83.22	$ 106.417 Millions	$ 1.279 Millions
Trulieve Cannabis Corp.	68.88	$ 1,139.040 Millions	$ 16.536 Millions

Date modified: 2026-09-03T12:21:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.